Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

Samsung Biologics to acquire PolyPeptide Group for KRW 2.71T

PRIVATEAug 27, 2026•about 3 hours ago

Acquiring Company

Samsung Biologics Ltd

Acquired Company

PolyPeptide Group

SwitzerlandManufacturingManufacturingBiotechnology

Description

Samsung Biologics announced an all-cash offer to acquire PolyPeptide Group for CHF 1.46 billion, aimed at expanding its portfolio into peptide-based therapeutics. The acquisition is part of a strategy to meet the growing global demand for diverse modalities. The company is raising KRW 3 trillion to fund this acquisition along with further expansion efforts.

Company Information

Company

Samsung Biologics Ltd

About

Samsung Biologics (KRX: 207940.KS) is a fully integrated CDMO offering state-of-the-art contract development, manufacturing, and laboratory testing services. With proven regulatory approvals, the largest capacity, and the fastest throughput, Samsung Biologics is an award-winning partner of choice and is uniquely able to support the development and manufacturing of biologics products at every stage of the process while meeting the evolving needs of biopharmaceutical companies worldwide. For more information, visit samsungbiologics.com.

Don't miss Samsung Biologics Ltd's next move

Get an email the moment Samsung Biologics Ltd makes an acquisition, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Predictive Intelligence
Strategic

ML-powered predictions for Samsung Biologics Ltd's next move

Learn about Strategic plan

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed

Frequently asked

Who acquired PolyPeptide Group?

PolyPeptide Group was acquired by Samsung Biologics Ltd. The deal was reported on August 27, 2026. Samsung Biologics (KRX: 207940.KS) is a fully integrated CDMO offering state-of-the-art contract development, manufacturing, and laboratory testing services. Samsung Biologics Ltd is privately held and operates in Manufacturing.

When did Samsung Biologics Ltd acquire PolyPeptide Group?

Samsung Biologics Ltd's acquisition of PolyPeptide Group was reported on August 27, 2026. Samsung Biologics announced an all-cash offer to acquire PolyPeptide Group for CHF 1.46 billion, aimed at expanding its portfolio into peptide-based therapeutics. The acquisition is part of a strategy to meet the growing global demand for diverse modalities. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does PolyPeptide Group do?

PolyPeptide Group specializes in the development and manufacturing of peptide-based therapeutics. The company offers services that include custom peptide synthesis and related technologies. It serves a global clientele in the biopharmaceutical sector. It is privately held, operating in Manufacturing, and is based in Switzerland.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.